{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:58Z","timestamp":1787246698254,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01778-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:28:45Z","timestamp":1779298125000},"page":"3923-3939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03349060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575871","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03796676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03627767","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04345367","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03422822","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem A.","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3494-4142","authenticated-orcid":false,"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1778_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.36849\/JDD.6408","volume":"21","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis. J Drugs Dermatol. 2022;21:172\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1778_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40257-022-00697-w","volume":"23","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. Evaluating the longitudinal course of atopic dermatitis: implications for clinical practice. Am J Clin Dermatol. 2022;23:459\u201368.","journal-title":"Am J Clin Dermatol"},{"key":"1778_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360.","journal-title":"Lancet"},{"key":"1778_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2021.10.058","volume":"87","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. DESCRIBE-AD: a novel classification framework for atopic dermatitis. J Am Acad Dermatol. 2022;87:541\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1778_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaad.2021.04.021","volume":"86","author":"MR Hong","year":"2022","unstructured":"Hong MR, Lei D, Yousaf M, Chavda R, Gabriel S, Silverberg JI. A real-world study of the longitudinal course of skin pain in adult atopic dermatitis. J Am Acad Dermatol. 2022;86:1123\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1778_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.anai.2020.07.005","volume":"125","author":"MR Hong","year":"2020","unstructured":"Hong MR, Lei D, Yousaf M, et al. A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice. Ann Allergy Asthma Immunol. 2020;125:686-92.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1778_CR7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/DER.0000000000000716","volume":"32","author":"MR Hong","year":"2021","unstructured":"Hong MR, Lei D, Yousaf M, et al. Reliability and longitudinal course of itch\/scratch severity in adults with atopic dermatitis. Dermatitis. 2021;32:S28-32.","journal-title":"Dermatitis"},{"key":"1778_CR8","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","volume":"139","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139:S49-57.","journal-title":"J Allergy Clin Immunol"},{"key":"1778_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"1778_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1778_CR11","unstructured":"Cibinqo (abrocitinib). Summary of product characteristics. Pfizer Europe MA EEIG; December 2021. Accessed May 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf."},{"key":"1778_CR12","unstructured":"Cibinqo (abrocitinib). Product monograph. Pfizer Canada ULC; June 2022. Accessed May 2026. https:\/\/pdf.hres.ca\/dpd_pm\/00066473.PDF."},{"key":"1778_CR13","unstructured":"Cibinqo (abrocitinib 100 mg film-coated tablets). Summary of product characteristics. Pfizer Limited; June 2025. Accessed May 2026. https:\/\/www.medicines.org.uk\/emc\/product\/12873\/smpc\/print."},{"key":"1778_CR14","unstructured":"Cibinqo (abrocitinib). Prescribing information. Pfizer Inc.; February 2023. Accessed May 2026. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16652."},{"key":"1778_CR15","unstructured":"Pfizer Inc. Japan\u2019s MHLW approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis. News release. Accessed December 9, 2025. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults."},{"key":"1778_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet. 2020;396:255\u201366.","journal-title":"Lancet"},{"key":"1778_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:863\u201373.","journal-title":"JAMA Dermatol"},{"key":"1778_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase\u00a0II and phase\u00a0III clinical trial program. Am J Clin Dermatol. 2021;22:693\u2013707.","journal-title":"Am J Clin Dermatol"},{"key":"1778_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase\u00a03 trial. J Am Acad Dermatol. 2022;86:104\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"1778_CR20","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase\u00a03 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37:2056\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1778_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101\u201312.","journal-title":"N Engl J Med"},{"key":"1778_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157:1165\u201373.","journal-title":"JAMA Dermatol"},{"key":"1778_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase\u00a03 trial. Lancet. 2022;400:273\u201382.","journal-title":"Lancet"},{"key":"1778_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4\u00a0years of exposure. Am J Clin Dermatol. 2024;25:639\u201354.","journal-title":"Am J Clin Dermatol"},{"key":"1778_CR25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s13555-023-00948-6","volume":"13","author":"MJ Gooderham","year":"2023","unstructured":"Gooderham MJ, Pink AE, Simpson EL, Silverberg JI, G\u00fcler E, Watkins M. Abrocitinib 100\u00a0mg once daily for moderate-to-severe atopic dermatitis: a review of efficacy and safety, and expert opinion on use in clinical practice. Dermatol Ther (Heidelb). 2023;13:1893\u2013907.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1778_CR26","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/DER.0000000000000770","volume":"32","author":"BS Kim","year":"2021","unstructured":"Kim BS, Silverberg JI, St\u00e4nder S, et al. Rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: results from pooled phase\u00a02b and 3 monotherapy studies. Dermatitis. 2021;32:S39-44.","journal-title":"Dermatitis"},{"key":"1778_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase\u00a02 randomized clinical trial. JAMA Dermatol. 2019;155:1371\u20139.","journal-title":"JAMA Dermatol"},{"key":"1778_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"188","author":"K Reich","year":"2023","unstructured":"Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023;188:208\u201317.","journal-title":"Br J Dermatol"},{"key":"1778_CR29","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase\u00a02b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37:2558\u201368.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01778-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:42Z","timestamp":1787243382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01778-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Legend of video abstract updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Eric L. Simpson has received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. Saleem A. Farooqui, Gary Chan, Pinaki Biswas, and Erman G\u00fcler are employees and shareholders of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols were reviewed and approved by the institutional review boards or ethics committees of the participating institutions. The studies were conducted in compliance with the ethical principles outlined in the Declaration of Helsinki of 1964 and its later amendments and all International Council for Harmonization Good Clinical Practice guidelines. All local regulatory requirements were followed. Informed consent was obtained from all participants of the individual studies included in this analysis.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}